Hematology & Big Data

Big data has the potential to enable health care systems to effectively transform towards value-based health care. The computer age has brought about the rapid generation of large amounts of easily accessible data from variable, quickly developing, digital and non-digital sources, often referred to as “big data”. Big data has immense, yet so far hardly utilised potential to improve almost all areas of human life, including health. Whether this potential can be exploited depends on the sophistication of methods and technologies available to process and use (make sense of) big data. Regardless of the frequently cited revolution of data-driven health care decision-making, there are still promises to be fulfilled. 

---

In Europe the key health policy objectives are the strengthening of health system effectiveness, accessibility, resilience, quality and performance. However, the health care systems  face significant challenges due to the high incidence of chronic diseases, ageing populations, rising cost of new drugs and widely varying health outcomes across the region. Amid these challenges, the focused application of big data has thpotential to enable health care systems to effectively transform towards value-based health care.

---

HARMONY is a European Network of Excellence that will harmonize data on various hematological malignancies. The Big Data platform that will be developed is foreseen to enable the rapid definition of promising treatment strategies for individual patients. Read more >>

 

---

“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient or categories of patients”

Jesús María Hernandez Rivas, Project Coordinator of HARMONY and Professor in Hematology at the University Medical Hospital of Salamanca, Spain.

---

“Big Data doesn’t mean collecting only large quantities. The quality of the data is much more important. Therefore HARMONY is open to associate partners that can provide high quality data”

Professor Guillermo Sanz, Co-coordinator of HARMONY and Professor in Hematology at the University Medical Hospital of Valencia, Spain explained.

---

“With 51 partners including 7 pharmaceutical companies and over 60 associated partners it is important to have a common understanding about the tasks and roles of each and everyone in the project”.

Pam Bacon from Celgene and member of the HARMONY Executive Committee and EPFIA co-lead.

---

Receive the latest news. Click here to subscribe!